Overview of Consolidated Financial Results for the Fiscal Year Ending March 2026 and Consolidated Earnings Forecast for the Fiscal Year Ending March 2027 — Presentation Materials | UBE Corporation (4208) timely disclosure

Worth reading

65In focus

0–100. This measures how worthwhile something is to read, not how good or bad the company is.

Direction

Mixed performance

Direction inferred from the company’s description.

Scale

¥100 million (year-on-year change in the operating income forecast for the fiscal year ending March 2027)

Wording

Conditional

How definitive the wording is.

Contents of this document

Financial results presentationFiscal years ending March 2026 and March 202711 items taken from the company’s own explanation

Financial Results Figures (The key points of this material are explained below)

Net Sales¥4,623 100 million-5.0%

Operating profit¥189 100 million+5.0%

Ordinary income¥375 100 million+67.7%

Net income¥239 100 million net income attributable to owners of the parent

Operating profit margin4.1%, up 0.4 percentage points year on year

Results for the three months of the current quarterRevenue: ¥130.2 billion for the fourth quarter alone; operating income: ¥4.0 billion for the fourth quarter alone

Full-year earnings forecast

Net Sales

¥4,850 100 million

EBITDA

¥565 100 million

Operating profit

¥235 100 million

Ordinary income

¥375 100 million

Net income

¥245 100 million net income attributable to owners of the parent

Annual dividendTo be determined

What the company explained in this material

Breakdown of Factors Affecting the ChangeReasons cited by the Company for the change in the figures.

Change in operating income for the fiscal year ended March 2026

Price difference¥44 100 million

Volume variance¥-48 100 million

Fixed costs and other factors¥13 100 million

Total¥9 100 million

Change in the operating income forecast for the fiscal year ending March 2027

Price difference¥-42 100 million

Volume variance¥170 100 million

Fixed costs and other factors¥-82 100 million

Total¥46 100 million

Assumptions Underlying the Business OutlookThe assumptions used by the company in preparing its forecast.

Exchange rate

Fiscal year ending March 2026¥150.8 /$

Fiscal year ending March 2027¥155 /$

Naphtha CIF

Fiscal year ending March 2026$604 /t

Fiscal year ending March 2027$750 /t

Domestic naphtha

Fiscal year ending March 2026¥65,100 /KL

Fiscal year ending March 2027¥82,500 /KL

Australian coal CIF

Fiscal year ending March 2026$139 /t

Fiscal year ending March 2027$145 /t

New initiatives

Expansion of the silicon nitride ceramics plant
Expansion of the separator plant
Construction of DMC and EMC plants in the United States
Expansion of the high-purity nitric acid plant
Suspension of caprolactam production and reduction of nylon polymer production in Thailand
Suspension of caprolactam and nylon polymer production and ammonia production in Japan

Key KPIsA metric the company considers important as a management benchmark.

EBITDA

Fiscal year ending March 2026¥464 100 million

Forecast for the fiscal year ending March 2027¥565 100 million

Year-on-year difference¥101 100 million

Capital expenditures

Fiscal year ending March 2026¥690 100 million

Forecast for the fiscal year ending March 2027¥850 100 million

Research and development costs

Fiscal year ending March 2026¥124 100 million

Forecast for the fiscal year ending March 2027¥130 100 million

Debt-to-equity ratio

Fiscal year ending March 20260.82 times

Forecast for the fiscal year ending March 20270.92 times

Equity ratio

Fiscal year ending March 202646.2 %

Forecast for the fiscal year ending March 202744.1 %

Segment results

Functional products

Net Sales619

Revenue unit¥100 million

Operating profit98

Operating profit unit¥100 million

Year-on-year change in revenue-6.4

Year-on-year operating profit growth-16.4

High-performance urethane

Net Sales465

Revenue unit¥100 million

Operating profit-5

Operating profit unit¥100 million

Year-on-year change in revenue198.1

Pharmaceuticals

Net Sales210

Revenue unit¥100 million

Operating profit-13

Operating profit unit¥100 million

Year-on-year change in revenue-33.3

Resins and chemicals

Net Sales2,512

Revenue unit¥100 million

Operating profit82

Operating profit unit¥100 million

Year-on-year change in revenue-8.2

Machinery

Net Sales684

Revenue unit¥100 million

Operating profit62

Operating profit unit¥100 million

Year-on-year change in revenue-21.3

Year-on-year operating profit growth-20.8

Other

Net Sales345

Revenue unit¥100 million

Operating profit19

Operating profit unit¥100 million

Year-on-year change in revenue-12

Year-on-year operating profit growth-6.9

Medium-term management plan targets

DOEAt least 2.5%

Consolidated total payout ratio30% or higher (previous medium-term management plan, three-year average)

Reduce GHG emissions50% reduction by fiscal 2030 (versus fiscal 2013)

Financial targets

ROE

Forecast for the fiscal year ending March 20275.5 %

ROIC

Forecast for the fiscal year ending March 20274 %

Debt-to-equity ratio

Forecast for the fiscal year ending March 20270.92 times

Equity ratio

Forecast for the fiscal year ending March 202744.1 %

Market Size / Share

Total domestic cement demand

Fiscal year ending March 20263,053 10,000 tonnes

Number of employees

Recruiting foreign nationals

Fiscal 2024 results5 people

Mid-career hiring ratio

Fiscal 2024 results51.3 %

Capital expenditures

¥690 100 million actual for the fiscal year ended March 2026; forecast of ¥85.0 billion for the fiscal year ending March 2027

Annual Dividend

Fiscal year ending March 2026¥110 per share

Forecast for the fiscal year ending March 2027To be determined

Breakdown for the fiscal year ended March 2026

Interim¥55 per share

End of period¥55 per share

Contents of this document
Item	Details
Document type	Financial results presentation
Fiscal Period Covered	Fiscal years ending March 2026 and March 2027
Net Sales	¥4,623 100 million (YoY -5.0%)
Operating profit	¥189 100 million (YoY +5.0%)
Ordinary income	¥375 100 million (YoY +67.7%)
Net income	¥239 100 million (net income attributable to owners of the parent)
Operating profit margin	4.1%, up 0.4 percentage points year on year
Results for the three months of the current quarter	Revenue: ¥130.2 billion for the fourth quarter alone; operating income: ¥4.0 billion for the fourth quarter alone
Full-year earnings forecast	Net Sales ¥4,850 100 million / EBITDA ¥565 100 million / Operating profit ¥235 100 million / Ordinary income ¥375 100 million / Net income ¥245 100 million (net income attributable to owners of the parent) / Annual dividend To be determined
Segment results	Functional products Net Sales 619 / Revenue unit ¥100 million / Operating profit 98 / Operating profit unit ¥100 million / Year-on-year change in revenue -6.4 / Year-on-year operating profit growth -16.4 / High-performance urethane Net Sales 465 / Revenue unit ¥100 million / Operating profit -5 / Operating profit unit ¥100 million / Year-on-year change in revenue 198.1 / Year-on-year operating profit growth Not disclosed / Pharmaceuticals Net Sales 210 / Revenue unit ¥100 million / Operating profit -13 / Operating profit unit ¥100 million / Year-on-year change in revenue -33.3 / Year-on-year operating profit growth Not disclosed / Resins and chemicals Net Sales 2,512 / Revenue unit ¥100 million / Operating profit 82 / Operating profit unit ¥100 million / Year-on-year change in revenue -8.2 / Year-on-year operating profit growth Not disclosed / Machinery Net Sales 684 / Revenue unit ¥100 million / Operating profit 62 / Operating profit unit ¥100 million / Year-on-year change in revenue -21.3 / Year-on-year operating profit growth -20.8 / Other Net Sales 345 / Revenue unit ¥100 million / Operating profit 19 / Operating profit unit ¥100 million / Year-on-year change in revenue -12 / Year-on-year operating profit growth -6.9
Breakdown of Factors Affecting the Change	Change in operating income for the fiscal year ended March 2026 Price difference ¥44 100 million / Volume variance ¥-48 100 million / Fixed costs and other factors ¥13 100 million / Total ¥9 100 million / Change in the operating income forecast for the fiscal year ending March 2027 Price difference ¥-42 100 million / Volume variance ¥170 100 million / Fixed costs and other factors ¥-82 100 million / Total ¥46 100 million
Key KPIs	EBITDA Fiscal year ending March 2026 ¥464 100 million / Forecast for the fiscal year ending March 2027 ¥565 100 million / Year-on-year difference ¥101 100 million / Capital expenditures Fiscal year ending March 2026 ¥690 100 million / Forecast for the fiscal year ending March 2027 ¥850 100 million / Research and development costs Fiscal year ending March 2026 ¥124 100 million / Forecast for the fiscal year ending March 2027 ¥130 100 million / Debt-to-equity ratio Fiscal year ending March 2026 0.82 times / Forecast for the fiscal year ending March 2027 0.92 times / Equity ratio Fiscal year ending March 2026 46.2 % / Forecast for the fiscal year ending March 2027 44.1 %
Number of employees	Recruiting foreign nationals Fiscal 2024 results 5 people / Mid-career hiring ratio Fiscal 2024 results 51.3 %
Assumptions Underlying the Business Outlook	Exchange rate Fiscal year ending March 2026 ¥150.8 /$ / Fiscal year ending March 2027 ¥155 /$ / Naphtha CIF Fiscal year ending March 2026 $604 /t / Fiscal year ending March 2027 $750 /t / Domestic naphtha Fiscal year ending March 2026 ¥65,100 /KL / Fiscal year ending March 2027 ¥82,500 /KL / Australian coal CIF Fiscal year ending March 2026 $139 /t / Fiscal year ending March 2027 $145 /t
Medium-term management plan targets	DOE At least 2.5% / Consolidated total payout ratio 30% or higher (previous medium-term management plan, three-year average) / Reduce GHG emissions 50% reduction by fiscal 2030 (versus fiscal 2013)
Financial targets	ROE Forecast for the fiscal year ending March 2027 5.5 % / ROIC Forecast for the fiscal year ending March 2027 4 % / Debt-to-equity ratio Forecast for the fiscal year ending March 2027 0.92 times / Equity ratio Forecast for the fiscal year ending March 2027 44.1 %
Annual Dividend	Fiscal year ending March 2026 ¥110 per share / Forecast for the fiscal year ending March 2027 To be determined / Breakdown for the fiscal year ended March 2026 Interim ¥55 per share / End of period ¥55 per share
Capital expenditures	¥690 100 million (actual for the fiscal year ended March 2026; forecast of ¥85.0 billion for the fiscal year ending March 2027)
Market Size / Share	Total domestic cement demand Fiscal year ending March 2026 3,053 10,000 tonnes
New initiatives	Expansion of the silicon nitride ceramics plant, Expansion of the separator plant, Construction of DMC and EMC plants in the United States, Expansion of the high-purity nitric acid plant, Suspension of caprolactam production and reduction of nylon polymer production in Thailand, Suspension of caprolactam and nylon polymer production and ammonia production in Japan

Items this document does not state (11)

Gross Profit MarginSelling, general and administrative expensesProgress against full-year forecastSelf-assessment against the planUnit price and quantity metricsNumber of stores and locationsRisk amount incorporated into the outlookPayout ratioAcquisition of treasury sharesOrders received and order backlogKey points of the Q&A

These are items the company does not state in this document. We do not leave them blank, nor fill them in from other sources or by inference.

The reasons the company gives

The company's own explanation, not something inferred from the numbers.

For the fiscal year ended March 2026, sales of high-performance urethanes increased following the acquisition of the Urethane Systems business, while operating income benefited from lower depreciation and amortization expenses due in part to impairment losses recognized in the previous fiscal year. These benefits were partly offset by weak sales of nylon polymers and other products, lower pharmaceutical sales volumes, and the machinery business no longer being included in the consolidated results. For the fiscal year ending March 2027, the Company expects higher sales volumes of functional products, a 12-month contribution from Urethane Systems, and an improved sales mix in contract pharmaceuticals.

How to read this page

This is not the documentKomori reads the disclosure the company filed and writes this summary. Figures are as stated by the company and are not audited.

Weight is not a verdictIt measures how much this changes what the company had already told the market. It is not a view on the shares.

Corrections happenIf the company reissues this disclosure, the page is rebuilt from the corrected version and the revision number moves up.